Supramolecular 4-methoxysalicylic acid tranexamic acid ionic salt, preparation method therefor, and use thereof
By constructing a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, the permeability and irritation issues of potassium 4-methoxysalicylic acid and tranexamic acid in skin applications have been solved, enabling wider application and stronger whitening effects.
Patent Information
- Application Number
- PCT/CN2025/088124
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-06
- Filing Date
- 2025-04-09
- Publication Date
- 2025-11-13
AI Technical Summary
Potassium 4-methoxysalicylate and tranexamic acid have problems with poor permeability, toxic side effects and irritation in skin applications, which limits their whitening and spot-removing effects.
By constructing a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, a novel compound is formed by tightly binding the 4-methoxysalicylic acid anion and the tranexamic acid cation through ionic bonds, thereby improving its stability in both solid and liquid phases. The compound is prepared by methods such as heating and stirring, ultrasonic treatment, and crystallization.
It effectively solves the permeability and irritation problems of potassium 4-methoxysalicylate and tranexamic acid, expands their application range, and enhances the effects of whitening, fading spots, removing yellowing, and fading acne scars.
Smart Images

Figure CN2025088124_13112025_PF_FP_ABST
Abstract
Description
Supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, its preparation method and application
[0001] Relevant publicly available cross-references
[0002] This disclosure claims priority to Chinese Patent Publication No. 202410549041X, filed on May 6, 2024, entitled "Supramolecular 4-methoxysalicylic acid tranexamic acid ion salt and its preparation method and application", the entire contents of which are incorporated herein by reference. Technical Field
[0003] This disclosure relates to the field of pharmaceutical and cosmetic compounds, and more specifically, to a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, its preparation method, and its application. Background Technology
[0004] Potassium 4-methoxysalicylate (4MSK) is a medicinal skin-whitening ingredient that works synergistically with keratinocyte metabolism, corrects abnormal epidermal proliferation, and promotes melanin excretion. By regulating the imbalance between keratinocyte proliferation and differentiation, it promotes melanin release, thereby achieving smoother, whiter skin. However, the high water solubility of 4MSK makes it difficult to penetrate the stratum corneum (SC) and be delivered to the epidermis. This presents a challenge for conventional topical 4MSK formulations in penetrating the stratum corneum barrier, and its low transdermal permeability limits its bioavailability. Furthermore, 4MSK has a certain degree of irritation, which also limits its dosage in products.
[0005] Tranexamic acid, also known as aminomethylformic acid, is a synthetic lysine analogue. Tranexamic acid not only possesses anti-secondary fibrinolytic efficacy but also inhibits plasminogen activation, thereby effectively alleviating UV radiation-induced melanin production and angiogenesis. Furthermore, tranexamic acid can reduce the activity of melanocyte tyrosinase by inhibiting prostaglandin production, thus achieving a skin-whitening and pigmentation-fading effect. In practical applications, transdermal administration is the primary method of using tranexamic acid products. However, topical tranexamic acid may cause adverse reactions such as local erythema, skin irritation, dryness, and desquamation.
[0006] Currently, both potassium 4-methoxysalicylate and tranexamic acid have certain toxic side effects and irritants. How to reduce their toxic side effects and irritants and achieve better results is a technical problem that needs to be solved in this field.
[0007] In view of this, this disclosure is hereby made.
[0008] Public content
[0009] The purpose of this disclosure is to provide a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, its preparation method and application, which aims to reduce the toxic side effects and irritation of potassium 4-methoxysalicylic acid and tranexamic acid, and to synergistically exert the effects of potassium 4-methoxysalicylic acid and tranexamic acid in removing spots, whitening, brightening, removing yellowing, fading acne marks and transdermal effects.
[0010] In a first aspect, this disclosure provides a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, wherein the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is a compound represented by the following structural formula, or a hydrate of a compound represented by the following structural formula:
[0011] This disclosure presents a novel compound, a supramolecular 4-methoxysalicylic acid-tranexamic acid ionic salt, constructed by combining the structures of 4-methoxysalicylic acid and tranexamic acid. In the supramolecular 4-methoxysalicylic acid-tranexamic acid ionic salt, the 4-methoxysalicylic acid anion and tranexamic acid cation are tightly bound by ionic bonds, which is beneficial to improving the stability of the 4-methoxysalicylic acid and tranexamic acid structures in the solid and liquid phases, and can effectively solve the problem of poor transdermal permeability of potassium 4-methoxysalicylate. Furthermore, this supramolecular 4-methoxysalicylic acid tranexamic acid ion salt can effectively reduce the toxic side effects and irritation of potassium 4-methoxysalicylate and tranexamic acid when used alone, greatly expanding their application range. The 4-methoxysalicylic acid structure in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt has a synergistic effect with the tranexamic acid structure, which can effectively enhance the whitening effect, brightening effect, spot-fading effect, yellowing-removing effect, acne scar fading effect, and transdermal effect compared to using potassium 4-methoxysalicylate or tranexamic acid alone.
[0012] In conjunction with the first aspect, in an optional embodiment of this disclosure, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is orthorhombic.
[0013] Secondly, this disclosure provides a method for preparing the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt provided in the first aspect above. The preparation method includes: sequentially heating and stirring a liquid phase containing 4-methoxysalicylic acid, tranexamic acid, and an organic solvent, followed by ultrasonic treatment to obtain a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution; and then subjecting the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution to crystallization treatment.
[0014] The preparation method of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt disclosed herein involves the reaction of 4-methoxysalicylic acid and tranexamic acid, resulting in the transfer of hydrogen atoms from 4-methoxysalicylic acid to tranexamic acid, causing proton transfer. This process combines the 4-methoxysalicylic acid structure with the tranexamic acid structure to form a novel compound, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt. This supramolecular 4-methoxysalicylic acid tranexamic acid ion salt not only effectively solves the problem of poor transdermal permeability of potassium 4-methoxysalicylate, but also effectively reduces the toxic side effects and irritation of potassium 4-methoxysalicylate and tranexamic acid when used alone, greatly expanding their application range. Furthermore, the 4-methoxysalicylic acid structure and the tranexamic acid structure in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt exhibit a synergistic effect, which, compared to using potassium 4-methoxysalicylate or tranexamic acid alone, can effectively enhance whitening, brightening, spot-fading, yellowing-reducing, acne scar-fading, and transdermal effects.
[0015] In conjunction with the second aspect, in an optional embodiment of this disclosure, the molar ratio of 4-methoxysalicylic acid to tranexamic acid is (3-1):(1-3).
[0016] In the above technical solution, the above ratio is conducive to the full reaction of 4-methoxysalicylic acid and tranexamic acid, which in turn helps to improve the yield and purity of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0017] In conjunction with the second aspect, in optional embodiments of this disclosure, the temperature of the heating and stirring treatment is 80–110°C; or / and the time of the heating and stirring treatment is 10–25 h.
[0018] In the above technical solution, the heating and stirring conditions facilitate the full combination of 4-methoxysalicylic acid and tranexamic acid, which in turn improves the conversion rate of the reaction between 4-methoxysalicylic acid and tranexamic acid, thereby improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0019] In conjunction with the second aspect, in optional embodiments of this disclosure, the temperature of the ultrasonic treatment is 40–60°C; or / and, the ultrasonic frequency of the ultrasonic treatment is 20–60 kHz; or / and, the ultrasonic power of the ultrasonic treatment is 280–320 W; or / and, the ultrasonic treatment time is 4–8 h.
[0020] In the above technical solution, the ultrasonic treatment conditions facilitate the further and more complete combination of 4-methoxysalicylic acid and tranexamic acid, resulting in a more thorough reaction. This is beneficial for further improving the conversion rate of the reaction between 4-methoxysalicylic acid and tranexamic acid, and consequently, for further improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0021] In conjunction with the second aspect, in optional embodiments of this disclosure, the temperature of the crystallization treatment is ≤0°C; or / and, the crystallization treatment is performed under vacuum conditions.
[0022] In the above technical solution, under the above crystallization treatment conditions, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution can be fully crystallized to precipitate crystals, which is beneficial to improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0023] In conjunction with the second aspect, in an optional embodiment of this disclosure, the method for preparing a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution further includes: after ultrasonic treatment, concentrating the ultrasonically treated system; or / and, the method for preparing a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt further includes: after crystallization treatment, sequentially filtering, washing, and drying the crystallized system.
[0024] In conjunction with the second aspect, in optional embodiments of this disclosure, the organic solvent includes at least one selected from methanol, ethanol, isopropanol, N-methylpyrrolidone, tetrahydrofuran, benzene, toluene, petroleum ether, n-hexane, acetone, dioxane, N,N-dimethyldiamide, ethyl acetate, and acetonitrile; and / or the preparation process of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is carried out under an inert gas atmosphere.
[0025] Optionally, the inert gas includes at least one of nitrogen, helium, neon, and argon.
[0026] Thirdly, this disclosure provides the use of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt provided in the first aspect above in the preparation of pharmaceuticals, cosmetics or skin care products.
[0027] The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt disclosed herein not only effectively solves the problem of poor transdermal permeability of potassium 4-methoxysalicylate, but also effectively reduces the toxic side effects and irritation of potassium 4-methoxysalicylate and tranexamic acid when used alone, greatly expanding their application range. In addition, the 4-methoxysalicylic acid structure and the tranexamic acid structure in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt have a synergistic effect, which can effectively enhance the whitening effect, brightening effect, spot-fading effect, yellowing-reducing effect, acne scar fading effect, and transdermal effect compared with the use of potassium 4-methoxysalicylate or tranexamic acid alone. Therefore, it can be used to prepare drugs, cosmetics, and skin care products with whitening, spot-fading, or acne scar fading effects. Attached Figure Description
[0028] To more clearly illustrate the technical solutions of the embodiments of this disclosure, the accompanying drawings used in the embodiments will be briefly described below. It should be understood that the following drawings only show some embodiments of this disclosure and should not be regarded as a limitation of the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.
[0029] Figure 1 is a flowchart of the preparation method of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt provided in this disclosure;
[0030] Figure 2 is a molecular structure diagram of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt prepared in Example 1.
[0031] Figure 3 shows the 1H NMR spectrum of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt prepared in Example 1.
[0032] Figure 4 shows the comparison of the rate of change of the facial brightness L value of the subjects in Experiment Example 6;
[0033] Figure 5 shows the comparison of the rate of change of facial erythema E value in subjects of Experiment Example 6;
[0034] Figure 6 shows the comparison of the rate of change of melanin M value in the face of the subjects in Experiment Example 6;
[0035] Figure 7 shows the comparison of the rate of change of ITA° values on the faces of the subjects in Experiment 6. Detailed Implementation
[0036] This disclosure provides a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, which is a compound represented by the following structural formula (Formula I), or a hydrate of a compound represented by the following structural formula (Formula I):
[0037] In this disclosure, in Formula I and They are bonded by ionic bonds.
[0038] In this disclosure, the chemical formula of Formula I is C 16 H 23 NO6; The chemical formula of the hydrate of Formula I is C 16 H 23 NO6·nH2O, where n is a natural number, and this disclosure does not limit the specific value of n.
[0039] This disclosure describes the construction of a novel compound, a supramolecular 4-methoxysalicylic acid-tranexamic acid ion salt, by combining the 4-methoxysalicylic acid structure with the tranexamic acid structure. In the supramolecular 4-methoxysalicylic acid-tranexamic acid ion salt, the 4-methoxysalicylic acid anion and the tranexamic acid cation are tightly bound by ionic bonds, which is beneficial to improving the stability of the 4-methoxysalicylic acid structure and the tranexamic acid structure in the solid and liquid phases. Therefore, the supramolecular 4-methoxysalicylic acid-tranexamic acid ion salt has strong chemical stability.
[0040] The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt disclosed herein not only effectively solves the problem of poor transdermal permeability of potassium 4-methoxysalicylate, but also effectively reduces the toxic side effects and irritation of potassium 4-methoxysalicylate and tranexamic acid when used alone. It has good cell and biocompatibility, high solubility and low irritation, which can reduce irritation and discomfort to the human body and greatly expand its application range. In addition, the 4-methoxysalicylic acid structure and the tranexamic acid structure in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt have a synergistic effect. Compared with the use of potassium 4-methoxysalicylate or tranexamic acid alone, it can improve the bioavailability of potassium 4-methoxysalicylate and tranexamic acid, has high permeability, can effectively reduce melanin production, and can effectively enhance whitening, brightening, spot fading, yellowing removal, acne scar fading and transdermal effects.
[0041] In this disclosure, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is a hydrate of formula I, and the chemical formula of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is C. 16 H 23 NO6·H2O (i.e., C) 16 H 25 NO7).
[0042] In this disclosure, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is orthorhombic.
[0043] As an example, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt has space group P212121 and cell parameters of [missing information]. α = 90°, β = 90°, γ = 90°, Z (number of units in the unit cell) = 4, and the unit cell volume is...
[0044] This disclosure provides a method for preparing the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt provided above. The preparation method includes: sequentially heating and stirring a liquid phase containing 4-methoxysalicylic acid, tranexamic acid, and an organic solvent, followed by ultrasonic treatment to obtain a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution; and then performing crystallization treatment on the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution.
[0045] The preparation method of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt disclosed herein involves the reaction of 4-methoxysalicylic acid and tranexamic acid, resulting in the transfer of hydrogen atoms from 4-methoxysalicylic acid to tranexamic acid, causing proton transfer. This process combines the 4-methoxysalicylic acid structure with the tranexamic acid structure to form a novel compound, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt. This supramolecular 4-methoxysalicylic acid tranexamic acid ion salt not only effectively solves the problem of poor transdermal permeability of potassium 4-methoxysalicylate, but also effectively reduces the toxic side effects and irritation of potassium 4-methoxysalicylate and tranexamic acid when used alone, greatly expanding their application range. Furthermore, the 4-methoxysalicylic acid structure and the tranexamic acid structure in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt exhibit a synergistic effect, which, compared to using potassium 4-methoxysalicylate or tranexamic acid alone, can effectively enhance whitening, brightening, spot-fading, yellowing-reducing, acne scar-fading, and transdermal effects.
[0046] Furthermore, the preparation method of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt provided in this disclosure is simple and easy to implement, and can improve the preparation efficiency of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0047] Figure 1 is a flowchart of the preparation method of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt provided in this disclosure. Referring to Figure 1, the preparation method of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt includes the following steps:
[0048] S110 involves sequentially heating and stirring a liquid phase containing 4-methoxysalicylic acid, tranexamic acid, and an organic solvent, followed by ultrasonic treatment, to obtain a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution.
[0049] In some optional embodiments of this disclosure, the method for preparing a liquid phase containing 4-methoxysalicylic acid, tranexamic acid, and an organic solvent includes: dispersing 4-methoxysalicylic acid and tranexamic acid in an organic solvent to obtain a 4-methoxysalicylic acid dispersion and a tranexamic acid dispersion, and then adding the 4-methoxysalicylic acid dispersion dropwise to the tranexamic acid dispersion to obtain a mixed solution as the liquid phase.
[0050] In this disclosure, the mixing uniformity of the liquid phase can be improved by first dispersing and then mixing.
[0051] In some optional embodiments of this disclosure, the molar ratio of 4-methoxysalicylic acid to tranexamic acid is (3-1):(1-3); the above ratio is conducive to the full reaction, and thus conducive to improving the yield and purity of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0052] As an example, the molar ratio of 4-methoxysalicylic acid to tranexamic acid can be any one of 1:3, 1:2, 1:1, 2:1 and 3:1 or any range between the two.
[0053] Optionally, in some optional embodiments of this disclosure, the molar ratio of 4-methoxysalicylic acid to tranexamic acid is 1:1. This ratio is more conducive to the full reaction of 4-methoxysalicylic acid and tranexamic acid, thereby further improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid-tranexamic acid ion salt.
[0054] In some optional embodiments of this disclosure, the organic solvent includes, but is not limited to, at least one selected from methanol, ethanol, isopropanol, N-methylpyrrolidone, tetrahydrofuran, benzene, toluene, petroleum ether, n-hexane, acetone, dioxane, N,N-dimethyldiamide, ethyl acetate, and acetonitrile.
[0055] As a typical but not limiting example, the organic solvent is selected from ethanol.
[0056] In some optional embodiments of this disclosure, the heating and stirring temperature is 80–110°C. The heating and stirring temperature within the above temperature range is conducive to the full combination of 4-methoxysalicylic acid and tranexamic acid, resulting in a more thorough reaction. This is beneficial to improving the conversion rate of the reaction between 4-methoxysalicylic acid and tranexamic acid, and thus to improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0057] As an example, the temperature of the heating and stirring process can be any value among 80°C, 85°C, 90°C, 95°C, 100°C, 105°C and 110°C or a range between any two.
[0058] In some optional embodiments of this disclosure, the heating and stirring process employs oil bath heating.
[0059] In some optional embodiments of this disclosure, the heating and stirring treatment time is 10 to 25 hours. The heating and stirring treatment time within the above-mentioned time range is conducive to the full combination of 4-methoxysalicylic acid and tranexamic acid, the reaction is more thorough, and the conversion rate of the reaction between 4-methoxysalicylic acid and tranexamic acid is improved, thereby improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0060] As an example, the heating and stirring time can be any value among 10h, 12h, 14h, 18h, 20h, 22h and 25h or a range between any two.
[0061] In this disclosure, ultrasonic treatment can accelerate the reaction rate of 4-methoxysalicylic acid and tranexamic acid, enabling the 4-methoxysalicylic acid anion and tranexamic acid cation to bind effectively through ionic bonds.
[0062] In some optional embodiments of this disclosure, the ultrasonic treatment temperature is 40–60°C. At this ultrasonic treatment temperature, it is beneficial for 4-methoxysalicylic acid and tranexamic acid to combine more fully, resulting in a more complete reaction. This is beneficial for further improving the conversion rate of the reaction between 4-methoxysalicylic acid and tranexamic acid, and consequently, for further improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0063] As an example, the temperature of the ultrasonic treatment can be any value among 40°C, 45°C, 50°C, 55°C and 60°C or a range between any two.
[0064] In some optional embodiments of this disclosure, the ultrasonic frequency of the ultrasonic treatment is 20–60 kHz. At the aforementioned ultrasonic frequency, 4-methoxysalicylic acid and tranexamic acid are more readily combined, resulting in a more thorough reaction. This improves the conversion rate of the reaction between 4-methoxysalicylic acid and tranexamic acid, and consequently, further enhances the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0065] As an example, the ultrasonic frequency of the ultrasonic treatment can be any value among 20kHz, 25kHz, 30kHz, 35kHz, 40kHz, 45kHz, 50kHz, 55kHz, and 60kHz, or any value in between.
[0066] In some optional embodiments of this disclosure, the ultrasonic power of the ultrasonic treatment is 280-320W. Under the ultrasonic power of the ultrasonic treatment, it is beneficial for 4-methoxysalicylic acid and tranexamic acid to combine more fully and for the reaction to be more thorough. This is beneficial for further improving the conversion rate of the reaction between 4-methoxysalicylic acid and tranexamic acid, and thus for further improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0067] As an example, the ultrasonic power of the ultrasonic treatment can be any value among 280W, 285W, 290W, 295W, 300W, 305W, 310W, 315W and 320W or a range between any two.
[0068] In some optional embodiments of this disclosure, the ultrasonic treatment time is 4 to 8 hours. The ultrasonic treatment time is conducive to the further and more complete combination of 4-methoxysalicylic acid and tranexamic acid, the reaction is more thorough, and the conversion rate of the reaction between 4-methoxysalicylic acid and tranexamic acid is further improved, which in turn is conducive to further improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0069] As an example, the duration of ultrasound treatment can be any value among 4h, 5h, 6h, 7h, and 8h, or a range between any two.
[0070] In some optional embodiments of this disclosure, the preparation method of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution further includes: concentrating the ultrasonically treated system after ultrasonic treatment. This method facilitates subsequent crystallization and promotes crystal precipitation.
[0071] As an example, the concentration process can be carried out using a reduced pressure concentration method.
[0072] In some optional embodiments of this disclosure, the ultrasonically treated system is concentrated to obtain a supersaturated supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution; the above method facilitates the rapid precipitation of crystals.
[0073] In some optional embodiments of this disclosure, the preparation process of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution is carried out under an inert gas atmosphere. The inert gas atmosphere helps to prevent the oxidation of 4-methoxysalicylic acid and tranexamic acid during the reaction, and helps to prevent the destruction of the biological activity of 4-methoxysalicylic acid and tranexamic acid. This can improve the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, and also helps to fully exert the whitening effect, brightening effect, spot fading effect, yellowing removal effect, acne scar fading effect and transdermal effect.
[0074] Optionally, the inert gas includes, but is not limited to, at least one of nitrogen, helium, neon, and argon.
[0075] In some optional embodiments of this disclosure, the preparation method of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution includes: dissolving 4-methoxysalicylic acid in the aforementioned organic solvent to obtain a first system, dissolving tranexamic acid in the aforementioned organic solvent to obtain a second system; then, adding the first system dropwise to the second system or adding the second system dropwise to the first system to obtain the aforementioned "liquid phase containing 4-methoxysalicylic acid, tranexamic acid and organic solvent".
[0076] S120 is used to crystallize a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution.
[0077] In some optional embodiments of this disclosure, the crystallization process employs a cooling crystallization method.
[0078] Optionally, the crystallization treatment temperature is ≤0℃; at the above crystallization temperature, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution can be fully crystallized to precipitate crystals, which is beneficial to improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0079] As an example, the crystallization treatment temperature is -20°C.
[0080] In some optional embodiments of this disclosure, the crystallization process is carried out under vacuum conditions; under the above-mentioned crystallization process conditions, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution can be fully crystallized to precipitate crystals, which is beneficial to improving the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt.
[0081] In some optional embodiments of this disclosure, the preparation method of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt further includes: after crystallization treatment, filtering, washing and drying the crystallized system in sequence.
[0082] As an example, the system after crystallization treatment can be washed with at least one of methanol, ethanol, isopropanol, N-methylpyrrolidone, tetrahydrofuran, benzene, toluene, petroleum ether, n-hexane, acetone, dioxane, N,N-dimethyldiamide, ethyl acetate, and acetonitrile.
[0083] In some optional embodiments of this disclosure, the preparation process of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is carried out under an inert gas atmosphere. An inert gas atmosphere helps to prevent the oxidation of 4-methoxysalicylic acid and tranexamic acid during the reaction, and helps to prevent the destruction of their biological activity. This, in turn, can improve the yield and purity of the obtained supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, and also helps to fully exert its whitening, brightening, spot-fading, yellowing-reducing, acne scar-fading, and transdermal effects. During the preparation process of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, inert gas can also be slowly added to maintain a constant temperature and pressure.
[0084] Optionally, the inert gas includes, but is not limited to, at least one of nitrogen, helium, neon, and argon.
[0085] This disclosure provides an application of the above-mentioned supramolecular 4-methoxysalicylic acid tranexamic acid ion salt in the preparation of pharmaceuticals, cosmetics or skin care products.
[0086] The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt disclosed herein not only effectively solves the problem of poor transdermal permeability of potassium 4-methoxysalicylate, but also effectively reduces the toxic side effects and irritation of potassium 4-methoxysalicylate and tranexamic acid when used alone, greatly expanding their application range. In addition, the 4-methoxysalicylic acid structure and the tranexamic acid structure in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt have a synergistic effect, which can effectively enhance the whitening effect, brightening effect, spot-fading effect, yellowing-reducing effect, acne scar fading and transdermal effect compared with the use of potassium 4-methoxysalicylate or tranexamic acid alone. Therefore, it can be used to prepare drugs, cosmetics and skin care products with whitening, spot-fading and acne scar fading effects.
[0087] In some optional embodiments of this disclosure, the aforementioned pharmaceuticals, cosmetics, and skincare products may include an aqueous solution of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt. As an example, the aqueous solution of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt can be prepared by mixing deionized water and supramolecular 4-methoxysalicylic acid tranexamic acid ion salt. The mass percentage of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt in the pharmaceuticals, cosmetics, or skincare products is 1-5%. As an example, the mass percentage of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt in the pharmaceuticals, cosmetics, or skincare products can be, for example, any value among 1%, 2%, 3%, 4%, and 5%, or a range between any two.
[0088] To make the objectives, technical solutions, and advantages of the embodiments of this disclosure clearer, the technical solutions in the embodiments of this disclosure will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.
[0089] Example 1
[0090] This embodiment provides a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, the preparation method of which includes the following steps:
[0091] 1 mol of 4-methoxysalicylic acid and 1 mol of tranexamic acid were dispersed in ethanol solutions to obtain 4-methoxysalicylic acid ethanol dispersion and tranexamic acid ethanol dispersion, respectively. The 4-methoxysalicylic acid ethanol dispersion was slowly added dropwise to the tranexamic acid ethanol dispersion to obtain a mixed solution. The mixed solution was placed in a reaction vessel and stirred in an oil bath at 80°C for 24 h under an argon atmosphere. Then, the reaction was ultrasonically reacted for 5 h under the conditions of an ultrasonic input power of 300 W, an ultrasonic frequency of 40 kHz, and an ultrasonic temperature of 40°C. As the reaction proceeded, argon gas was slowly added to ensure that the temperature and pressure inside the vessel remained constant. Subsequently, the reaction solution was concentrated under reduced pressure to obtain a supersaturated solution. The supersaturated solution was subjected to low-temperature crystallization at -20°C. The precipitated ionic salt compound was filtered, washed three times with refrigerated ethanol solvent, and dried in a vacuum drying oven at 60°C to obtain supramolecular 4-methoxysalicylic acid tranexamic acid ionic salt.
[0092] Example 2
[0093] This embodiment provides a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, the preparation method of which includes the following steps:
[0094] 1 mol of 4-methoxysalicylic acid and 1 mol of tranexamic acid were dispersed separately in ethanol solutions to obtain 4-methoxysalicylic acid ethanol dispersion and tranexamic acid ethanol dispersion, respectively. The 4-methoxysalicylic acid ethanol dispersion was slowly added dropwise to the tranexamic acid ethanol dispersion to obtain a mixed solution. The mixed solution was placed in a reaction vessel and stirred in an oil bath at 80°C for 12 h under an argon atmosphere. Then, the reaction was ultrasonically reacted for 5 h under the conditions of an ultrasonic input power of 300 W, an ultrasonic frequency of 40 kHz, and an ultrasonic temperature of 50°C. As the reaction proceeded, argon gas was slowly added to ensure that the temperature and pressure inside the vessel remained constant. Subsequently, the reaction solution was concentrated under reduced pressure to obtain a supersaturated solution. The supersaturated solution was subjected to low-temperature crystallization at -20°C. The precipitated ionic salt compound was filtered, washed three times with refrigerated ethanol solvent, and dried in a vacuum drying oven at 60°C to obtain supramolecular 4-methoxysalicylic acid tranexamic acid ionic salt.
[0095] Example 3
[0096] This embodiment provides a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, the preparation method of which includes the following steps:
[0097] 1 mol of 4-methoxysalicylic acid and 2 mol of tranexamic acid were dispersed separately in ethanol solutions to obtain 4-methoxysalicylic acid ethanol dispersion and tranexamic acid ethanol dispersion, respectively. The 4-methoxysalicylic acid ethanol dispersion was slowly added dropwise to the tranexamic acid ethanol dispersion to obtain a mixed solution. The mixed solution was placed in a reaction vessel and stirred in an oil bath at 90°C for 12 h under an argon atmosphere. Then, the reaction was ultrasonically reacted for 5 h under the conditions of an ultrasonic input power of 300 W, an ultrasonic frequency of 40 kHz, and an ultrasonic temperature of 50°C. As the reaction proceeded, argon gas was slowly added to ensure that the temperature and pressure inside the vessel remained constant. Subsequently, the reaction solution was concentrated under reduced pressure to obtain a supersaturated solution. The supersaturated solution was subjected to low-temperature crystallization at -20°C. The precipitated ionic salt compound was filtered, washed three times with refrigerated ethanol solvent, and dried in a vacuum drying oven at 60°C to obtain supramolecular 4-methoxysalicylic acid tranexamic acid ionic salt.
[0098] Comparative Example 1
[0099] This comparative example is potassium 4-methoxysalicylate.
[0100] Comparative Example 2
[0101] This comparative example uses tranexamic acid.
[0102] Comparative Example 3
[0103] This comparative example is a mixture of potassium 4-methoxysalicylate and tranexamic acid in a molar ratio of 1:1.
[0104] Experimental Example 1
[0105] The melting point of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt obtained in Example 1 was tested, and its melting point was 185-190℃, which meets the conditions for an ion salt.
[0106] The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt obtained in Example 1 was subjected to X-ray single crystal diffraction test using an X-ray diffractometer (SuperNova, Dual, Mo at zero, Atlas S2 diffractometer). The test temperature was 170.00 (10) K. The structure analysis was performed using Olex2 and ShelXL. The molecular structure diagram of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt obtained in Example 1 is shown in Figure 2. The X-ray single crystal test results of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt obtained in Example 1 are shown in Table 1.
[0107] Table 1 Single crystal data of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt prepared in Example 1
[0108] Atomic coordinates (×10) of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystal prepared in Example 1 4 and equivalent isotropic atomic displacement parameters The analysis data is shown in Table 2. U(eq) is defined as orthogonal U ij One-third of the trace amount of tensor.
[0109] Table 2. Atomic coordinates and isotropic atomic displacement parameters of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystals prepared in Example 1.
[0110] The anisotropic atomic displacement parameter analysis data of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystal prepared in Example 1 are shown in Table 3. The anisotropic atomic displacement factor is expressed as: 2π2[h2a*2U11+2hka*b*U12+…].
[0111] Table 3. Anisotropic atomic displacement parameters of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystals prepared in Example 1.
[0112] The bond length analysis data of each chemical bond in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystal prepared in Example 1 are shown in Table 4.
[0113] Table 4. Bond lengths of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystals prepared in Example 1.
[0114] The bond angle analysis data of each chemical bond in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystal prepared in Example 1 are shown in Table 5.
[0115] Table 5. Bond angles of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystals prepared in Example 1.
[0116] The hydrogen bond analysis data of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystals prepared in Example 1 are shown in Table 6.
[0117] Table 6. Hydrogen bonds in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystals prepared in Example 1.
[0118] The analysis data of the torsion angles of each chemical bond in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystal prepared in Example 1 are shown in Table 7.
[0119] Table 7. Bond torsion angles of the supramolecular 4-methoxysalicylic acid tranexamic acid salt single crystals prepared in Example 1.
[0120] Hydrogen atom coordinates of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystal prepared in Example 1 and various isotropic atomic displacement parameters The analyzed data is shown in Table 8.
[0121] Table 8. Hydrogen atom coordinates and isotropic atomic displacement parameters of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt single crystals prepared in Example 1.
[0122] The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt prepared in Example 1 was characterized by 1H NMR spectroscopy, and the 1H NMR spectrum is shown in Figure 3.
[0123] The NMR data in Figure 3 are as follows: 1 H NMR (600MHz, DMSO-d6) δ7.61(d,J=8.3Hz,1H),6.49–6.15(m,2H),3.71(s,3H),2.68(d,J=6.9Hz,2H),2.13(tt,J=12.1,3.6Hz,1H),1.90(dd,J= 13.6, 3.6Hz, 2H), 1.81 (dd, J = 13.5, 3.6Hz, 2H), 1.54 ( dqd, J = 11.3, 7.3, 3.4Hz, 1H), 1.26 ( qd, J = 13.2, 3.4Hz, 2H), 0.96 ( qd, J = 13.1, 3.5Hz, 2H).
[0124] Figure 3 shows the signals from the three hydrogen atoms on the phenolic ring of 4-methoxysalicylic acid and the methoxy substitution on the benzene ring, the hydrogen atom on the nitrogen atom of tranexamic acid, the two methines and four methylenes on the six-membered ring, and one methylene on the side chain; the remaining peaks are from a small amount of residual deuterated reagent, and no obvious impurity peaks were observed. This indicates that in the supramolecular 4-methoxysalicylic acid-tranexamic acid ion salt prepared in Example 1, 4-methoxysalicylic acid and tranexamic acid exist in a 1:1 molecular ratio, and its purity exceeds 98%.
[0125] Experiment Example 2: Cytotoxicity Detection
[0126] The steps for cytotoxicity testing are as follows:
[0127] (1) Prepare test samples of different concentrations.
[0128] Sample 1 to be tested: The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt obtained in Example 1 was dissolved in Gibco cell culture medium and prepared into different concentrations. The concentrations of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt in the liquid phase were 0.0195 mg / mL, 0.0391 mg / mL, 0.0781 mg / mL, 0.1563 mg / mL, 0.3125 mg / mL and 0.625 mg / mL, respectively.
[0129] Sample 2: Tranexamic acid from Comparative Example 2 was dissolved in Gibco cell culture medium and prepared into different concentrations. The concentrations of tranexamic acid in the liquid phase were 0.0195 mg / mL, 0.0391 mg / mL, 0.0781 mg / mL, 0.1563 mg / mL, 0.3125 mg / mL and 0.625 mg / mL, respectively.
[0130] Sample 3: Potassium 4-methoxysalicylate from Comparative Example 1 was dissolved in Gibco cell culture medium and prepared into different concentrations. The concentrations of potassium 4-methoxysalicylate in the liquid phase were 0.0195 mg / mL, 0.0391 mg / mL, 0.0781 mg / mL, 0.1563 mg / mL, 0.3125 mg / mL and 0.625 mg / mL, respectively.
[0131] (2) Cell inoculation
[0132] Human melanocytes were inoculated at a dose of 1×10 4 Seed cells at a density of 1 cell / well and incubate overnight in a 96-plate incubator (37°C, 5% CO2, 95% RH).
[0133] (3) Administration
[0134] When the cell deposition rate in the 96-well plate reaches 40%–60%, administer the drug; after drug administration, place the 96-well plate in an incubator (37°C, 5% CO2, 95% RH) for culture.
[0135] In the control group, 200 μL of cell culture medium was added to each well; in the positive control group, 200 μL of cell culture medium containing 10 wt% DMSO was added to each well; in the test sample group, 200 μL of different concentrations of test sample 1, test sample 2, and test sample 3 were added to each well; the zeroing well was not seeded with cells, but only 200 μL of cell culture medium was added. Each different concentration of test sample was set up in 3 replicate wells.
[0136] (4) Detection
[0137] After culturing the cells for 24 hours, discard the supernatant, add MTT working solution (0.5 mg / mL), and incubate at 37°C in the dark for 4 hours. After incubation, discard the supernatant, add 150 μL of DMSO to each well, and read the OD value at 490 nm.
[0138] Cell viability (%) = [(OD of drug administration well - OD of zeroing well) / (OD of blank control well - OD of zeroing well)] × 100%; where the drug administration well is the positive control group or the sample group to be tested.
[0139] The cytotoxicity results of different concentrations of sample 1 are shown in Table 9.
[0140] Table 9. Cytotoxicity of different concentrations of sample 1
[0141] The cytotoxicity results of different concentrations of sample 2 are shown in Table 10.
[0142] Table 10 Cytotoxicity of Sample 2 at different concentrations
[0143] The cytotoxicity results of different concentrations of sample 3 are shown in Table 11.
[0144] Table 11 Cytotoxicity of Test Sample 3 at Different Concentrations
[0145] As can be seen from Tables 9 to 11, the cytotoxicity of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt of Example 1 is lower than that of potassium 4-methoxysalicylate of Comparative Example 1 and tranexamic acid of Comparative Example 2, indicating that the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt of Example 1 is more suitable for skin application.
[0146] Experiment Example 3: Detection of Melanin Content
[0147] The steps for detecting melanin content are as follows:
[0148] (1) Liquid preparation and grouping
[0149] Blank control (BC): Gibco cell culture medium.
[0150] Positive control (PC): Glycyrrhizin was dissolved in cell culture medium, and the concentration of glycyrrhizin in the positive control solution was 125 μg / mL.
[0151] Sample 1 to be tested: The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt obtained in Example 1 was dissolved in cell culture medium. The concentrations of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt in Sample 1 to be tested were 0.078 mg / mL, 0.156 mg / mL and 0.313 mg / mL, respectively.
[0152] Test Sample 2: Tranexamic acid from Comparative Example 2 was dissolved in cell culture medium. The concentrations of tranexamic acid in Test Sample 2 were 0.078 mg / mL, 0.156 mg / mL, and 0.313 mg / mL, respectively.
[0153] Sample 3: Potassium 4-methoxysalicylate from Comparative Example 1 was dissolved in cell culture medium. The concentrations of potassium 4-methoxysalicylate in Sample 3 were 0.078 mg / mL, 0.103 mg / mL, and 0.156 mg / mL, respectively.
[0154] (2) Cell inoculation
[0155] With 2.2×10 5 Cells were seeded at a rate of 1 melanocyte / well into 6-well plates and incubated overnight in an incubator (37°C, 5% CO2, 95% RH).
[0156] (3) Administration
[0157] When the cell deposition rate in the 6-well plate reached 40%–60%, the cells were divided into groups and administered the drug. Each well received 2 mL of drug, with 3 replicates per group. The cells were then incubated for 72 hours in an incubator (37℃, 5% CO2, 95% RH).
[0158] (4) Sample collection
[0159] After culturing, discard the remaining culture medium in each well. Add 700 μL of 0.25% trypsin to each well to digest the melanocytes. Digest at 37°C for 1–2 min. Collect the cells into 1.5 mL centrifuge tubes and centrifuge at 10,000 rpm for 10 min. Discard the supernatant. Add 200 μL of distilled water, 500 μL of anhydrous ethanol, and 500 μL of diethyl ether to each tube, mix well, incubate at room temperature for 30 min, and then centrifuge at 10,000 rpm for 10 min.
[0160] (5) Dissolve
[0161] Discard the supernatant and add 1 mL of 1 mol / L NaOH aqueous solution containing 10 wt% (volume fraction) DMSO to obtain the test samples for each group. Heat each group of test samples and melanin standard solutions of different concentrations in an 80℃ water bath for 30 min.
[0162] (6) Reading
[0163] Take 200 μL of suspension from each sample tube and put it into a 96-well plate, set up 2 replicates, and measure the absorbance at 405 nm using an ELISA reader.
[0164] Based on the concentration and absorbance values of the standard, a melanin content-absorbance standard curve was plotted. The sample OD value was substituted into the standard curve to calculate the melanin content. Statistical analysis was performed, and the results are shown in Table 12.
[0165] Table 12 Results of cell melanin synthesis inhibition rate
[0166] As shown in Table 12, compared with group BC, the melanin content in group PC was significantly reduced (P<0.0001), indicating that this experiment was effective. Compared with group BC, the melanin content of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt in Example 1 was significantly reduced, and the effect was significantly better than potassium 4-methoxysalicylate and tranexamic acid, indicating that supramolecular 4-methoxysalicylic acid tranexamic acid ion salt has better whitening and spot-fading effects.
[0167] Experiment Example 4: Transdermal Efficacy Test
[0168] The steps for transdermal efficacy testing are as follows:
[0169] (1) The skin on the back of GF Kunming mice was carefully peeled off, the subcutaneous fat layer and connective tissue were rinsed with physiological saline and placed in physiological saline for later use.
[0170] (2) Transdermal experiments were conducted using the Franz cell method. The exposed area of mouse skin in the diffusion cell of the Franz diffusion apparatus was 1.13 cm². 2 The receiving chamber has a volume of 15 mL.
[0171] (3) Take 1.0 mL of the test solution and apply it to the skin surface. Add 15 mL of commercially available PBS buffer solution (pH≈7.4) to the receiving cell and place it in a constant temperature water bath at 32℃ with a stirring speed of 350 rad / min. The samples obtained from Experimental Examples 1-2 and Comparative Examples 1-3 are dissolved in the aqueous solution to obtain a 3 wt% concentration of the test solution.
[0172] (4) Test of subcutaneous permeation: 2 mL of receiving liquid was taken at different time points, and three samples were taken at each time point. 2 mL of receiving liquid was added to the receiving chamber immediately after sampling. The concentration of receiving liquid was measured by liquid phase detection after the receiving liquids taken at different time points were filtered through a 0.22 μm microporous membrane.
[0173] The results of the transdermal efficacy test are shown in Table 13.
[0174] Table 13 Transdermal Efficacy Test Results
[0175] As can be seen from Table 13, the transdermal effect of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt of Example 1 is significantly better than that of potassium 4-methoxysalicylate in Comparative Example 1, tranexamic acid in Comparative Example 2, and the mixture of potassium 4-methoxysalicylate and tranexamic acid in Comparative Example 3, indicating that the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt has a better transdermal effect.
[0176] Experimental Example 5: Patch Test
[0177] The steps for patch testing are as follows:
[0178] (1) Select qualified patch test equipment and use the closed patch test method to place 0.020g to 0.025g of the test substance in the patch test equipment and apply it to the flexor side of the subject's forearm with low-allergenic adhesive tape.
[0179] In this case, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt of Example 1 was dissolved in deionized water to form an aqueous solution of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt with a concentration of 3wt%.
[0180] (2) Remove the test substance after 24 hours and observe the skin reaction at 0.5h, 24h and 48h after removal. Record the results according to the skin reaction grading standard in the "Cosmetic Safety Technical Specifications" (2015 edition) (as shown in Table 14).
[0181] Table 14 Grading Criteria for Skin Reactions in Skin Occlusive Patch Tests
[0182] The statistical results of the patch test are shown in Table 15.
[0183] Table 15 Patch Test Results
[0184] As can be seen from Table 15, when a 3wt% aqueous solution of supramolecular 4-methoxysalicylic acid tranexamic acid ion salt from Example 1 was prepared for a closed patch test on human skin, 0 cases of adverse skin reactions occurred in 40 participants; this indicates that the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt has low irritation.
[0185] Experiment Example 6: Whitening and Spot-Fading Effect Test
[0186] (1) Subject selection criteria
[0187] Volunteers aged 18 to 60 years who met the experimental requirements, with or without epidermal pigmentation in the forearm test area, were tested five times at different locations within the intended test area using a tristimulus colorimeter, with an average ITA° value between 10 and 41. Subject information is shown in Table 16.
[0188] Table 16 Subject Information
[0189] (2) Whitening and spot-fading effect testing environment
[0190] The whitening and spot-fading effects were tested in the laboratory at a temperature of 20–22°C and a relative humidity of 40%–60%.
[0191] (3) Requirements during testing
[0192] Preparations that may affect the whitening and spot-removing test should not be used on the test site.
[0193] Subjects are prohibited from ingesting any preparations that may affect the whitening and spot-removing test via intravenous drip, injection, oral administration, or other means.
[0194] Subjects primarily engaged in indoor activities, avoiding prolonged exposure to sunlight.
[0195] (4) Preparation of the test sample
[0196] The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt of Experimental Example 1 was formulated into an essence according to the essence formula (as shown in Table 17).
[0197] Table 17 Serum Formula
[0198] (5) Sample application method
[0199] Apply 1.5mL of the product evenly to the face every morning and evening.
[0200] (6) Detect skin data
[0201] Skin color and facial data of the subjects before product use were collected immediately after a single use of the test sample (i.e., 0 days), 7 days later, 14 days later, 21 days later, and 24 days later, respectively, using a skin color meter (XJJC-EQ-029) and a face scanner (XJJC-EQ-030).
[0202] (7) Statistical methods
[0203] Statistical analysis software was used to perform statistical analysis on the data. Quantitative data were expressed as mean ± standard deviation and tested for normality. If the data met the normality requirement, paired t-tests were used for comparisons of the data before and after the test; otherwise, rank-sum tests of two related samples were used. Ordinal data were compared before and after the test using rank-sum tests of two related samples. Comparisons between the test and control areas were performed using independent samples t-tests or rank-sum tests. Simultaneously, the regression coefficients (slope k-values) of each parameter over time were calculated, with a significance level of P < 0.05 for all parameters.
[0204] The results of the comparison of the change rate of facial brightness L value of the subjects are shown in Figure 4. As can be seen from Figure 4, after 7 days of using the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt essence, the facial brightness L value of the subjects increased, and the growth rate was higher than that of the blank essence group (facial area without essence application), indicating that using the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt essence for 7 days can have a brightening effect on the skin.
[0205] Figure 5 shows the comparison of the rate of change in E values of facial erythema in the subjects. As can be seen from Figure 5, after using the serum containing supramolecular 4-methoxysalicylic acid tranexamic acid ions for 14 days, the E values of facial erythema in the subjects decreased, and the rate of decrease was higher than that in the blank serum group (facial areas without serum application), indicating that the serum containing supramolecular 4-methoxysalicylic acid tranexamic acid ions can effectively lighten erythema after 14 days.
[0206] Figure 6 shows the comparison of the rate of change in melanin M values on the faces of the subjects. As can be seen from Figure 6, after using the serum containing supramolecular 4-methoxysalicylic acid tranexamic acid ions for 7 days, the melanin M values on the faces of the subjects decreased, and the rate of decrease was higher than that in the blank serum group (facial areas without serum application), indicating that using the serum containing supramolecular 4-methoxysalicylic acid tranexamic acid ions for 7 days can have a melanin-lightening effect.
[0207] Figure 7 shows the comparison of the rate of change in the ITA° value of the subjects' faces. As can be seen from Figure 7, after using the serum containing supramolecular 4-methoxysalicylic acid tranexamic acid ions for 7 days, the ITA° value of the subjects' faces continued to rise, and the rate of increase was much higher than that of the blank serum group (the facial area without serum application), indicating that using the serum containing supramolecular 4-methoxysalicylic acid tranexamic acid ions for 7 days can have a whitening effect on the skin.
[0208] Experiment 7: Clinical trial of treatment for melasma
[0209] The clinical testing steps for treating melasma are as follows:
[0210] (1) Screening of subjects
[0211] First, a preliminary diagnosis of melasma was performed on the 40 recruited volunteers. Qualified participants completed informed consent forms. Participants rested for 30 minutes in an environment with a temperature of 21±1℃ and a relative humidity of 50±10%RH.
[0212] Then, the VISIA skin image analyzer is used to scan the facial skin. Utilizing the Mirror medical imaging system, it groups skin types by age, employs cyclical facial photography techniques and a small magnifying glass tool to quantitatively analyze redness, pores, and UV reflection points, accurately diagnosing subtle skin problems and providing a clear qualitative analysis report.
[0213] (2) Applying the sample
[0214] According to the cream formulation in Table 18, a cream was prepared using the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt of Example 1 (referred to as the experimental group cream).
[0215] Table 18 Cream Formulas
[0216] The subjects were treated with a cream. One side of their face was covered with a commercially available cream for treating melasma (referred to as the control group cream), while the other side was covered with the experimental group cream.
[0217] The subjects were followed up 7, 14 and 28 days after applying the cream daily (subjects could not wash their faces within 48±4 hours before the visit), and their facial skin condition was photographed and scored. Subjects also completed questionnaires.
[0218] The following requirements apply after applying the cream:
[0219] Do not squeeze or rub the skin on your face, as this can damage the skin and cause infection.
[0220] Avoid exposing facial skin to excessive ultraviolet radiation.
[0221] Avoid eating spicy and irritating foods, as well as smoking and drinking alcohol.
[0222] The statistical results of the questionnaire survey on the treatment of melasma are shown in Table 19.
[0223] Table 19 Statistical Results of Questionnaire Survey on Treatment of Melasma
[0224] As can be seen from Table 19, the cream formulated with supramolecular 4-methoxysalicylic acid tranexamic acid ion salt of Example 1 (i.e., the experimental group cream) has the effect of treating melasma and is significantly better than a commercially available melasma-removing cream (i.e., the experimental group cream); indicating that supramolecular 4-methoxysalicylic acid tranexamic acid ion salt has a good effect on removing melasma.
[0225] In summary, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt provided in this disclosure not only effectively solves the problem of poor transdermal permeability of potassium 4-methoxysalicylate, but also effectively reduces the toxic side effects and irritation of potassium 4-methoxysalicylate and tranexamic acid when used alone, greatly expanding their application range. In addition, the 4-methoxysalicylic acid structure and the tranexamic acid structure in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt have a synergistic effect, which can effectively enhance the whitening effect, brightening effect, spot-fading effect, yellowing-reducing effect, acne scar fading effect, and transdermal effect compared with the use of potassium 4-methoxysalicylate or tranexamic acid alone. Therefore, it can be used to prepare drugs, cosmetics, and skin care products with whitening, spot-fading, and acne scar fading effects.
[0226] The embodiments described above are some, but not all, of the embodiments of this disclosure. The detailed description of the embodiments of this disclosure is not intended to limit the scope of the claimed disclosure, but merely to illustrate selected embodiments of the disclosure. All other embodiments obtained by those skilled in the art based on the embodiments of this disclosure without inventive effort are within the scope of protection of this disclosure.
[0227] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, this disclosure will not describe the various possible combinations separately. Industrial applicability
[0228] In summary, the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt provided in this disclosure not only effectively solves the problem of poor transdermal permeability of potassium 4-methoxysalicylate, but also effectively reduces the toxic side effects and irritation of potassium 4-methoxysalicylate and tranexamic acid when used alone, greatly expanding their application range. Furthermore, the 4-methoxysalicylic acid structure and the tranexamic acid structure in the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt have a synergistic effect, which, compared to using potassium 4-methoxysalicylate or tranexamic acid alone, can effectively enhance whitening, brightening, spot-fading, yellowing-reducing, acne scar-fading, and transdermal effects. Therefore, it can be used to prepare drugs, cosmetics, and skincare products with whitening, spot-fading, and acne scar-fading effects.
Claims
1. A supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, characterized in that, The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is a compound represented by the following structural formula, or the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is a hydrate of a compound represented by the following structural formula:
2. The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt according to claim 1, characterized in that, The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is orthorhombic.
3. The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt according to any one of claims 1-2, characterized in that, The chemical formula of formula I is C 16 H 23 NO6, the chemical formula of the hydrate of formula I is C 16 H 23 NO6·nH2O, where n is a natural number.
4. The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt according to any one of claims 1-3, characterized in that, The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt belongs to space group P212121, and its unit cell parameters are as follows: α = 90°, β = 90°, γ = 90°, Z (number of units in the unit cell) = 4, and the unit cell volume is...
5. A method for preparing the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt according to any one of claims 1-4, characterized in that, include: The liquid phase containing 4-methoxysalicylic acid, tranexamic acid and organic solvent was subjected to heating, stirring and ultrasonic treatment in sequence to obtain a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution. The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution was subjected to crystallization treatment.
6. The preparation method according to claim 5, characterized in that, The molar ratio of 4-methoxysalicylic acid to tranexamic acid is (3-1):(1-3).
7. The preparation method according to any one of claims 5-6, characterized in that, The temperature for the heating and stirring treatment is 80–110°C; Or / and, the heating and stirring treatment time is 10 to 25 hours; Or / and, the heating and stirring process is performed using an oil bath.
8. The preparation method according to any one of claims 5-7, characterized in that, The temperature for ultrasonic treatment is 40–60°C; Or / and, the ultrasonic frequency of the ultrasonic treatment is 20 to 60 kHz; Or / and, the ultrasonic power of the ultrasonic treatment is 280-320W; Or / and, the duration of the ultrasonic treatment is 4 to 8 hours.
9. The preparation method according to any one of claims 5-8, characterized in that, The temperature of the crystallization treatment is ≤0℃; Or / and, the crystallization process is performed under vacuum conditions.
10. The preparation method according to any one of claims 5-9, characterized in that, The preparation method of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt solution further includes: after the ultrasonic treatment, concentrating the ultrasonically treated system. Or / and, the preparation method of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt further includes: after the crystallization treatment, the system after the crystallization treatment is sequentially filtered, washed and dried.
11. The preparation method according to any one of claims 5-10, characterized in that, The organic solvent includes at least one selected from methanol, ethanol, isopropanol, N-methylpyrrolidone, tetrahydrofuran, benzene, toluene, petroleum ether, n-hexane, acetone, dioxane, N,N-dimethyldiamide, ethyl acetate, and acetonitrile. Or / and, the preparation process of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is carried out under an inert gas atmosphere; Optionally, the inert gas includes at least one of nitrogen, helium, neon, and argon.
12. The preparation method according to any one of claims 5-11, characterized in that, The method for preparing the liquid phase containing 4-methoxysalicylic acid, tranexamic acid and an organic solvent includes: dispersing the 4-methoxysalicylic acid and the tranexamic acid in the organic solvent to obtain a 4-methoxysalicylic acid dispersion and a tranexamic acid dispersion, and then adding the 4-methoxysalicylic acid dispersion dropwise to the tranexamic acid dispersion to obtain a mixed solution as the liquid phase.
13. The preparation method according to any one of claims 5-12, characterized in that, In the preparation of the supramolecular 4-methoxysalicylic acid tranexamic acid ion salt, an inert gas is added to maintain constant temperature and pressure.
14. The use of a supramolecular 4-methoxysalicylic acid tranexamic acid ion salt as described in any one of claims 1-4 in the preparation of pharmaceuticals, cosmetics or skin care products.
15. The application according to claim 14, characterized in that, The supramolecular 4-methoxysalicylic acid tranexamic acid ion salt is present in pharmaceuticals, cosmetics, or skincare products at a mass percentage of 1-5%.
Citation Information
Patent Citations
Supramolecular tranexamic acid mandelic acid ionic salt as well as preparation method and application thereof
CN116217379A
Supramolecular tranexamic acid glycolic acid ionic salt as well as preparation method and application thereof
CN116284814A
Supramolecular 4-methoxy salicylic acid tranexamic acid ionic salt as well as preparation method and application thereof
CN118439948A
Skin care preparation for external use
JP2010202565A
Composition comprising polydatin and tranexamic acid for whitening skin
KR1020150012785A
